●TOR signalling in bugs, brain and brawn. Jacinto, E. & Hall, M. N. Nature Reviews Molecular Cell Biology February (2003). TOR — the target of the anticancer drug rapamycin — controls the growth of mammalian cells. This review explores the signalling pathway in yeast, brain and muscle cells.

●Wnts and TGFβ: old friends signalling at new places. Packard, M., Mathew, D. & Budnik, V. Nature Reviews Neuroscience February (2003)

●Molecular imaging in drug discovery and development. Rudin, M. & Weissleder, R. Nature Reviews Drug Discovery February (2003)

●Inflammation and cancer. Coussens, L. M. & Werb, Z. Nature 19/26 December 2002 This review article describes the link between the tumour microenvironment, principally inflammatory cells, and tumour progression, and discusses how inflammation might be targeted to prevent or treat cancer.

●The sigmoidal curve of cancer. Stock, R. P. & Bialy, H. Nature Biotechnology January (2003) This commentary discusses the involvement of aneuploidy — long since relegated to the back bench of cancer research — in the initiation and progression of cancer.

●Harnessing immunity for cancer marker discovery. Hanash, S. Nature Biotechnology January (2003) This News and Views article describes the identification of prostate-specific antigens, using phage display.

●Alloreactive killer cells: hindrance and help for haematopoietic transplants. Parham, P. & McQueen, K. L. Nature Reviews Immunology February (2003)

●Of eponyms, acronyms and orthonyms. Turnpenny, P. & Smith, R. Nature Reviews Genetics February (2003) This opinion article discusses how medical genetic syndromes are named and asks whether credit is always given to those who first describe a syndrome.